Biosimilars Updates

Regularly updated biosimilars material, in addition to our annual outputs. Includes specific information on ranibizumab for ocular use.

Understand the area

Understanding biological and biosimilar medicines

Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions

Ranibizumab for ocular use

Resources to specifically support the introduction of ranibizumab biosimilar for ocular use.

Preparing to use ranibizumab biosimilar

Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.

Good governance when implementing ranibizumab biosimilar

Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance.

The licence and supporting evidence for ranibizumab biosimilars

A licensed ranibizumab biosimilar is available from Teva: Ongavia. Learn about the licensed indications and supporting evidence.

All our resources

All our resources on biosimilar medicines

Implementing ustekinumab biosimilar

Good governance when implementing ustekinumab biosimilar

The licence and supporting evidence for ustekinumab biosimilars

Preparing to use ustekinumab biosimilar

Good governance when implementing eculizumab biosimilar

The licence and supporting evidence for eculizumab biosimilars

Preparing to use eculizumab biosimilar

Good governance when implementing tocilizumab biosimilar

The licence and supporting evidence for tocilizumab biosimilar

Preparing to use tocilizumab biosimilar

SPS - Specialist Pharmacy Service

NHS

Biosimilars Updates

Understand the area

Ranibizumab for ocular use

All our resources

Learn more about us or ask for help

Medicines Tools